行情

NMTR

NMTR

9 Meters Biopharma
NASDAQ

实时行情|Nasdaq Last Sale

1.300
+0.050
+4.00%
盘后: 1.300 0 0.00% 19:55 09/16 EDT
开盘
1.250
昨收
1.250
最高
1.300
最低
1.240
成交量
167.03万
成交额
--
52周最高
2.260
52周最低
0.6300
市值
3.31亿
市盈率(TTM)
-8.7542
分时
5日
1月
3月
1年
5年
9 Meters Biopharma, Inc. 将出席奥本海默秋季医疗保健生命科学与医疗技术峰会
Conference Dates: September 20th-23rd
ACCESSWIRE · 1天前
9 Meters Biopharma, Inc. 将出席 HC Wainwright 第 23 届年度全球投资大会
\- Conference Dates: September 13th-15th -RALEIGH, NC / ACCESSWIRE / September 8, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Company's CEO, John Temp...
ACCESSWIRE · 09/08 12:15
9 Meters Biopharma, Inc. 将参加花旗 2021 年第 16 届年度生物制药虚拟会议
\- Conference Dates: September 08th-10th -RALEIGH, NC / ACCESSWIRE / September 1, 2021 / 9 Meters Biopharma, Inc. (Nasdaq:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Company's CEO, John Temp...
ACCESSWIRE · 09/01 12:15
医疗保健行业的 5 只价值股
The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most...
Benzinga · 08/23 14:20
ATHE、NMTR 和 PXLW 位居前列
GeoVax Labs (NASDAQ:GOVX) +75% presents COVID-19 vaccine data at the European Society of Medicine (ESMED) General Assembly Marin Software MRIN +25% integrates with Criteo's ecommerce media platform for advertising SunLink Health Systems (NYSE:SSY)
Seekingalpha · 08/20 12:21
9 Meters Biopharma 与 EBRIS 基金会合作开展 Larazotide 试验,用于治疗儿童 COVID-19 相关并发症
Benzinga · 08/16 19:12
HVBT、PSTI 和 DPW 是上市前的赢家
Enlivex Therapeutics ENLV +22% to launch Phase IIb Allocetra trial for COVID-19 patients in Israel ADMA Biologics ADMA +17% on FDA approval for plasma collection facility in Maryville, TN Travere Therapeutics TVTX +17% meets primary efficacy
Seekingalpha · 08/16 12:42
9 Meters Biopharma, Inc. 宣布与 EBRIS 基金会合作,计划开展 Larazotide 治疗由 COVID-19 引起的儿童多系统炎症综合征 (MIS-C) 的第 2 期研究
9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, today
Benzinga · 08/16 12:16
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解NMTR最新的财务预测,通过NMTR每股收益,每股净资产,每股现金流等数据分析9 Meters Biopharma近期的经营情况,然后做出明智的投资选择。
分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测NMTR价格均价为4.583,最高价位6.00,最低价为3.000。
EPS
机构持股
总机构数: 102
机构持股: 7,442.72万
持股比例: 29.22%
总股本: 2.55亿
类型机构数股数
增持
30
2,208.36万
建仓
33
776.42万
减持
14
1,883.12万
平仓
25
1,256.11万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+0.83%
制药与医学研究
+0.11%
高管信息
Non-Executive Chairman/Independent Director
Mark Sirgo
President/Chief Executive Officer/Director
John Temperato
Chief Financial Officer
Edward Sitar
Independent Director
Michael Constantino
Independent Director
Lorin Johnson
Independent Director
Michael Rice
暂无数据
NMTR 简况
9 Meters Biopharma Inc(原名:Innovate Biopharmaceuticals Inc)是一家胃肠平台公司。该公司从事为罕见疾病和未满足需求的患者开发治疗方案。其产品包括短肠综合征和腹腔疾病候选药物,以及NM-002、Larazotide、NM-003和NM-004。NM-002是用于短肠综合征(SBS)的长效可注射GLP-1类似物。Larazotide是用于腹腔疾病的口服和肠道受限的紧密连接调节剂。NM-003是处于罕见药下的GLP-2类似物。NM -004是一种免疫调节剂,在溃疡性结肠炎中被称为儿科罕见药。

微牛提供9 Meters Biopharma Inc(NASDAQ-NMTR)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的NMTR股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易NMTR股票基本功能。